How to buy Biodesix stock | $14.45

Biodesix, Inc is a diagnostics & research business based in the US. Biodesix shares (BDSX) are listed on the NASDAQ and all prices are listed in US Dollars. Biodesix employs 200 staff and has a trailing 12-month revenue of around 0.00.

Biodesix stock price (NASDAQ: BDSX)

Use our graph to track the performance of BDSX stocks over time.

Biodesix shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$14.45
52-week range	$8.85 - $31.99
50-day moving average	$12.96
200-day moving average	$17.92
Wall St. target price	$27.33
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Biodesix shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Biodesix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Biodesix, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Biodesix price performance over time

Historical closes compared with the close of $14.45 from 2021-05-28

1 week (2021-07-20)	N/A
1 month (2021-07-01)	13.07%
3 months (2021-04-30)	-11.67%
6 months (2021-01-27)	N/A

1 year (2020-07-27)	N/A
2 years (2019-07-27)	N/A
3 years (2018-07-27)	N/A
5 years (2016-07-27)	N/A

Biodesix financials

Revenue TTM	$69.3 million
Gross profit TTM	$23.6 million
Return on assets TTM	-14.95%
Return on equity TTM	-1089.34%
Profit margin	-41.26%
Book value	$1.36
Market capitalisation	$241.7 million

TTM: trailing 12 months

Shorting Biodesix shares

There are currently 498,825 Biodesix shares held short by investors – that's known as Biodesix's "short interest". This figure is 14.6% down from 584,221 last month.

There are a few different ways that this level of interest in shorting Biodesix shares can be evaluated.

Biodesix's "short interest ratio" (SIR)

Biodesix's "short interest ratio" (SIR) is the quantity of Biodesix shares currently shorted divided by the average quantity of Biodesix shares traded daily (recently around 182052.91970803). Biodesix's SIR currently stands at 2.74. In other words for every 100,000 Biodesix shares traded daily on the market, roughly 2740 shares are currently held short.

To gain some more context, you can compare Biodesix's short interest ratio against those of similar companies.

• Biocept (BIOC.US): 1.29
• Veracyte (VCYT.US): 4.92
• Biogen (BIIB.US): 1.01

However Biodesix's short interest can also be evaluated against the total number of Biodesix shares, or, against the total number of tradable Biodesix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biodesix's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Biodesix shares in existence, roughly 20 shares are currently held short) or 0.0647% of the tradable shares (for every 100,000 tradable Biodesix shares, roughly 65 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Biodesix.

Find out more about how you can short Biodesix stock.

Biodesix share dividends

We're not expecting Biodesix to pay a dividend over the next 12 months.

Biodesix overview

Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc.

Frequently asked questions

What percentage of Biodesix is owned by insiders or institutions?
Currently 72.571% of Biodesix shares are held by insiders and 15.813% by institutions. How many people work for Biodesix?
Latest data suggests 200 work at Biodesix. When does the fiscal year end for Biodesix?
Biodesix's fiscal year ends in December. Where is Biodesix based?
Biodesix's address is: 2970 Wilderness Place, Boulder, CO, United States, 80301 What is Biodesix's ISIN number?
Biodesix's international securities identification number is: US09075X1081